You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

DEPOCYT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Depocyt, and when can generic versions of Depocyt launch?

Depocyt is a drug marketed by Pacira Pharms Inc and is included in one NDA.

The generic ingredient in DEPOCYT is cytarabine. There are fifteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the cytarabine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Depocyt

A generic version of DEPOCYT was approved as cytarabine by HIKMA on August 2nd, 1989.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for DEPOCYT?
  • What are the global sales for DEPOCYT?
  • What is Average Wholesale Price for DEPOCYT?
Drug patent expirations by year for DEPOCYT
Recent Clinical Trials for DEPOCYT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Kartos Therapeutics, Inc.Phase 1/Phase 2
University of FloridaPhase 2
Medical College of WisconsinPhase 1

See all DEPOCYT clinical trials

US Patents and Regulatory Information for DEPOCYT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pacira Pharms Inc DEPOCYT cytarabine INJECTABLE, LIPOSOMAL;INJECTION 021041-001 Apr 1, 1999 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for DEPOCYT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pacira Pharms Inc DEPOCYT cytarabine INJECTABLE, LIPOSOMAL;INJECTION 021041-001 Apr 1, 1999 ⤷  Sign Up ⤷  Sign Up
Pacira Pharms Inc DEPOCYT cytarabine INJECTABLE, LIPOSOMAL;INJECTION 021041-001 Apr 1, 1999 ⤷  Sign Up ⤷  Sign Up
Pacira Pharms Inc DEPOCYT cytarabine INJECTABLE, LIPOSOMAL;INJECTION 021041-001 Apr 1, 1999 ⤷  Sign Up ⤷  Sign Up
Pacira Pharms Inc DEPOCYT cytarabine INJECTABLE, LIPOSOMAL;INJECTION 021041-001 Apr 1, 1999 ⤷  Sign Up ⤷  Sign Up
Pacira Pharms Inc DEPOCYT cytarabine INJECTABLE, LIPOSOMAL;INJECTION 021041-001 Apr 1, 1999 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for DEPOCYT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Pacira Limited DepoCyte cytarabine EMEA/H/C/000317
Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease.
Withdrawn no no no 2001-07-11
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for DEPOCYT

See the table below for patents covering DEPOCYT around the world.

Country Patent Number Title Estimated Expiration
Brazil PI0414551 ⤷  Sign Up
Japan 2007524589 ⤷  Sign Up
Canada 2277956 PROCEDE SERVANT A UTILISER DES LIPIDES NEUTRES AFIN DE MODIFIER LA LIBERATION IN VIVO DEPUIS DES LIPOSOMES A VESICULES MULTIPLES (METHOD FOR UTILIZING NEUTRAL LIPIDS TO MODIFY IN VIVO RELEASE FROM MULTIVESICULAR LIPOSOMES) ⤷  Sign Up
Norway 329401 ⤷  Sign Up
Denmark 1670433 ⤷  Sign Up
Canada 2538856 FORMULATION PHARMACEUTIQUE TRANSDERMIQUE VISANT A REDUIRE LES RESIDUS SUR LA PEAU (TRANSDERMAL PHARMACEUTICAL FORMULATION FOR MINIMIZING SKIN RESIDUES) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for DEPOCYT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3300601 2022C/528 Belgium ⤷  Sign Up PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827
3300601 LUC00271 Luxembourg ⤷  Sign Up PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; AUTHORISATION NUMBER AND DATE: EU/1/18/1308 20180827
1744764 2018/042 Ireland ⤷  Sign Up PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180823
3300601 2022027 Norway ⤷  Sign Up PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REG. NO/DATE: EU/1/18/1308 20180831
1744764 300960 Netherlands ⤷  Sign Up PRODUCT NAME: COMBINATIE VAN DAUNORUBICINE EN CYTARABINE; REGISTRATION NO/DATE: EU/1/18/1308 20180827
2768484 SPC/GB19/067 United Kingdom ⤷  Sign Up PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTERED: UK EU/1/18/1308(FOR NI) 20180827; UK PLGB 31626/0004 20180827
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.